Google News Alert for: Simcere Pharmaceutical (SCR)
Piper Jaffray Upgraded Simcere Pharmaceutical (SCR) to Buy
StreetInsider.com (subscription) - Birmingham,MI,USA
Piper Jaffray upgraded Simcere Pharmaceutical (NYSE: SCR) from Neutral to Buy with an $18 price target, in transferred coverage. The firm said, "We believe ...
See all stories on this topic
This as-it-happens Google Alert is brought to you by Google.
Create another alert.
Manage your alerts.
